Pharmaceutical

Request for TOC Request for Sample
BUY NOW

Global Mycobacterium Abscessus Treatment Market – Industry Trends and Forecast to 2029

Pharmaceutical | Upcoming Report | Sep 2022 | Global | 350 Pages | No of Tables: 220 | No of Figures: 60

Report Description

Global Mycobacterium Abscessus Treatment Market, By Drugs (Isoniazid, Ethambutol, Rifampin, Others), Indication (Tuberculosis, Leprosy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029

Get Exclusive Sample Copy of this Report Here

Mycobacterium Abscessus Treatment Market Analysis and Size

The global mycobacterium abscessus treatment market is expected to witness significant growth during the forecast period. Rising prevalence of mycobacterium infections worldwide and in emerging markets are the factors responsible for the growth of this market. The market is on the rise due to increase in the surgical procedures, R&D activities funded by government and rise in the population in this region. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global mycobacterium abscessus treatment market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Mycobacterium abscessus is a bacterium which is mostly related to the ones that cause tuberculosis and Hansen’s Disease (Leprosy). Various healthcare-associated infections happen due to this bacterium, usually consisting of the skin and the soft tissues under the skin. It is also a cause of serious lung infections in people with several chronic lung diseases, such as cystic fibrosis.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Drugs (Isoniazid, Ethambutol, Rifampin, Others), Indication (Tuberculosis, Leprosy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

AstraZeneca (U.K.), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), GSK plc (U.K.), Hikma Pharmaceuticals PLC (U.K.), Cipla Inc. (India)

Market Opportunities

  • Increasing Treatment Approaches
  • Increasing Demand for Retail Pharmacies

Global Mycobacterium Abscessus Treatment Market Dynamics

Drivers

  • Increased Cases of Mycobacterium abscessus

The increasing prevalence of mycobacterium abscessus is expected to boost the market's growth. Around 4.66–5.78% of population were witnessing mycobacterium infections at the end of 2020 globally.  

  • Growing Demand for Advanced Diagnostic Techniques

Scientists are developing advanced techniques for the betterment of the patients. DNA fingerprinting technology is an efficient diagnostic tool that is used for diagnosing these infections. Precise diagnosis and accurate identification of the disease-causing mycobacterial species lead to the decision of the right treatment.

Opportunities

  • Increasing Treatment Approaches

There are several antibiotics that are useful for the treatment of these infectious diseases. Researchers are continuously taking efforts on gaining a proper treatment solution for several mycobaterial infections. The market for mycobacterial infections treatment is progressively growing due to increased prevalence of infectious diseases and limited treatment options. This creates more opportunity to the market.

  • Increasing Demand for Retail Pharmacies

Rise in the number of perinatal infections therapeutics being delivered through retail pharmacies and surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

  • Lack of skilled professionals

The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global mycobacterium abscessus treatment market over a forecast period.

  • High Cost

The huge expenditure associated with mycobacterium abscessus medications surely hamper the market growth.

This global mycobacterium abscessus treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global mycobacterium abscessus treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Mycobacterium Abscessus Treatment Market       

Considering the present scenario, COVID-19 has left a major global public health crisis that has impacted practically every business. Its long-term consequences are expected to influence industry growth during the forecast period.

Although during the pandemic, the attention was driven towards the COVID-19 patients majorly and hospitals and clinics were occupied with these patients but in the post-pandemic era, the biotechnology and pharmaceutical industries are expected to witness a huge growth in the future, as research and treatments are drifting again towards the normal patients. Thus, this will significantly impact the global mycobacterium abscessus treatment market.

Global Mycobacterium Abscessus Treatment Market Scope

The global mycobacterium abscessus treatment market is segmented on the basis of drug, indication, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

  • Isoniazid
  • Ethambutol
  • Rifampin
  • Others

Indication

  • Tuberculosis
  • Leprosy
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Mycobacterium Abscessus Treatment Market Regional Analysis/Insights

The global mycobacterium abscessus treatment market is analysed and market size insights and trends are provided by drug, indication, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global mycobacterium abscessus treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for global mycobacterium abscessus treatment market throughout the forecasted period due to rising prevalence of the disease.  

Asia-Pacific dominates the market due to increased WHO & government awareness programs in the regions.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Mycobacterium Abscessus Treatment Market Share Analysis

The global mycobacterium abscessus treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global mycobacterium abscessus treatment market

Key players operating in the global mycobacterium abscessus treatment market include:

  • AstraZeneca (U.K.)
  • Lilly (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sanofi (France)
  • Novartis AG (Switzerland)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Aurobindo Pharma (India)
  • Lupin (India)
  • Merck & Co., Inc. (U.S.)
  • Pfizer Inc. (U.S.)
  • GSK plc (U.K.)
  • Hikma Pharmaceuticals PLC (U.K.)
  • Cipla Inc. (India)


SKU-

Table of Content

Please fill in the below form for detailed Table of Content

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country

List of Table

Please fill in the below form for detailed List of Table

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country

List of Figure

Please fill in the below form for detailed List of Figure

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country

View Infographics

Please fill in the below form for detailed Infographics

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country
CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19